DE3364240D1 - Cytotoxic medicine containing at least one immune toxine and chloroquine - Google Patents

Cytotoxic medicine containing at least one immune toxine and chloroquine

Info

Publication number
DE3364240D1
DE3364240D1 DE8383400459T DE3364240T DE3364240D1 DE 3364240 D1 DE3364240 D1 DE 3364240D1 DE 8383400459 T DE8383400459 T DE 8383400459T DE 3364240 T DE3364240 T DE 3364240T DE 3364240 D1 DE3364240 D1 DE 3364240D1
Authority
DE
Germany
Prior art keywords
toxine
chloroquine
immune
medicine containing
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8383400459T
Other languages
German (de)
English (en)
Inventor
Franz Jansen
Pierre Gros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Application granted granted Critical
Publication of DE3364240D1 publication Critical patent/DE3364240D1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8383400459T 1982-03-10 1983-03-07 Cytotoxic medicine containing at least one immune toxine and chloroquine Expired DE3364240D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8204047A FR2522968B1 (fr) 1982-03-10 1982-03-10 Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine

Publications (1)

Publication Number Publication Date
DE3364240D1 true DE3364240D1 (en) 1986-07-31

Family

ID=9271836

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8383400459T Expired DE3364240D1 (en) 1982-03-10 1983-03-07 Cytotoxic medicine containing at least one immune toxine and chloroquine

Country Status (8)

Country Link
US (1) US4582703A (enExample)
EP (1) EP0088694B1 (enExample)
JP (1) JPS59500370A (enExample)
AT (1) ATE20519T1 (enExample)
DE (1) DE3364240D1 (enExample)
FR (1) FR2522968B1 (enExample)
NO (1) NO834087L (enExample)
WO (1) WO1983003055A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
CA1314245C (en) * 1984-05-23 1993-03-09 Franz Jansen Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
CA1335227C (en) * 1987-06-22 1995-04-11 Wylie W. Vale, Jr. Crf analog conjugates
WO1990010457A1 (en) * 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
US5112607A (en) * 1991-06-05 1992-05-12 The United States Of America As Represented By The Secretary Of The Army Potentiation of immunotoxin action by Brefeldin A
GB0507672D0 (en) * 2005-04-15 2005-05-25 Barnaba Vincenzo Adjuvant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine

Also Published As

Publication number Publication date
JPH0455172B2 (enExample) 1992-09-02
US4582703A (en) 1986-04-15
FR2522968A1 (fr) 1983-09-16
FR2522968B1 (fr) 1986-03-28
WO1983003055A1 (fr) 1983-09-15
EP0088694A1 (fr) 1983-09-14
EP0088694B1 (fr) 1986-06-25
NO834087L (no) 1983-11-09
JPS59500370A (ja) 1984-03-08
ATE20519T1 (de) 1986-07-15

Similar Documents

Publication Publication Date Title
GR3002487T3 (en) Medicament with anti-tumoral action containing hexadecylphosphocholine
ZA878952B (en) Metal complex-containing pharmaceutical agents
ZA832135B (en) Norscopine ethers,processes for their preparation and pharmaceutical compositions thereof
DE3377134D1 (en) Polysaccharide concentrates, process for their preparation and medicinal and cosmetic compositions containing them
IE862554L (en) Pharmaceutical compositions
OA08714A (en) Cyclic-1,3-dione derivatives, compositions containing them and their use as herbicides.
GR3035682T3 (en) Non-glycosylated fgf-4 and compositions containing the same.
BE894175A (fr) Nouvelles imidazotetrazinones, leur preparation et les medicaments qui les contiennent.
IL100364A0 (en) Benzodiazepinones,their preparation and pharmaceutical compositions containing them
IL61930A (en) 25-hydroxy-26,26,26,27,27,27-hexafluorocholecalciferol and pharmaceutical compositions containing it
ES8502340A1 (es) Procedimiento de obtencion deuna vacuna que contiene vitaminas y compuestos de cinc y de selenio fisiologicamente compatibles.
IL63368A0 (en) 4,5-diaryl-alpha-polyfluoroalkyl-1h-imidazole-2-methanamines,their preparation and pharmaceutical compositions containing them
DE3364240D1 (en) Cytotoxic medicine containing at least one immune toxine and chloroquine
IL61361A0 (en) N-aryl-n'-imidazol-2-ylureas, their preparation and pharmaceutical compositions containing them
IL67940A0 (en) 2,3-diaryl-5-halo-thiophenes,their preparation and pharmaceutical compositions containing them
NZ208669A (en) Human calcitonin 2, and pharmaceutical compositions
DE3372708D1 (en) Cytotoxic medicines containing at least one immune toxine and one amine
IL67528A (en) 2-oxo-1-(aminocarbonylaminosulfonylaminocarbonyl)azetidines,processes for their preparation and pharmaceutical compositions containing the same
IL63773A (en) Penicillanoyloxymethyl penicillanate 1,1,1',1'-tetraoxide,its preparation and pharmaceutical compositions containing it
IL62660A (en) 4,5-diaryl-alpha(polyfluoroalkyl)-1h-pyrrole-2-methanamines,their preparation and pharmaceutical compositions containing them
IL64563A0 (en) 3,4-bis-substituted 1,2,5-oxidiazole 2-oxides,their preparation and pharmaceutical compositions containing them
DE3363563D1 (en) Medicines containing an association of at least one immunotoxine and at least one monovalent carboxylic ionophore
IL64252A (en) 3,3-dimethyl-indolin-2-ones,their preparation and pharmaceutical compositions containing them
IL66385A0 (en) Benzotriazoles,their preparation and pharmaceutical compositions containing them
JPS57150650A (en) Peptide, medicinal composition and use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee